Abstracts obtained from the derivation versus the validation samples. The construct validity of the DRCI was assessed by comparing it to only demographics, a comorbidity-index, and the revised Chronic Disease Score (CDS). Wilcoxon matched-pairs signedrank test was used to determine differences between the median squared residual scores between the various risk-adjustment models. RESULTS: The correlation between actual and predicted costs between the derivation and validation samples was not statistically different for the three predicted outcomes. Age and sex accounted for 0.8% and 0.1% of the variance in total and ambulatory cost. The comorbidity index and the CDS individually explained approximately 6%-10% of the variance in total and ambulatory cost, respectively. The DRCI explained 6%-8% of the variance in total and ambulatory costs, and did significantly (p < 0.05) better than only demographics. The added variance explained by the incorporation of the comorbidity index or CDS accounted for 5%-8% of the variance in total and ambulatory costs, respectively. CONCLUSIONS: The predictive validity of the DRCI is equivalent to that of the CDS. When the DRCI was used along with the CDS, up to eight percent of variability in costs and utilization were explained. This may suggest that the DRCI and the CDS may be explaining different dimensions of a subject's severity of diabetes. Southern Arizona VA Health Care System, Tucson, AZ, USA OBJECTIVES: The fifth leading cause of death by disease in the U.S., type-2 diabetes places patients at higher risk for heart disease, blindness, kidney failure, extremity amputations, and other chronic conditions. The 2002 costs associated with diabetes were estimated at US$132 billion. Predictive models incorporating clinical measures of diabetes severity from clinical databases and their association to health care resource use and costs are needed for health plan resource planning and management. The purpose of this study was to determine the relationship between health care resource use and costs with diabetes-related clinical measures, and to develop a diabetes resource consumption index (DRCI). The DRCI consists of empirically derived weights to predict health care use among persons with diabetes. METHODS: The data was collected from four outpatient clinics within the Southern Arizona Veterans Affairs Health care System. The DRCI models used diabetes severity measures to predict three health care resource outcomes: risk of hospitalization; total health care costs; and ambulatory costs. Severity of diabetes was defined as the function of annual HbA1C, creatinine clearance-rate, and cholesterol values. Comorbidity was defined as the number of concurrent secondary diseases. The log-likelihood ratio test and the Wald test-statistic were used to assess the performance of the models. RESULTS: A total of 367 diabetic subjects had complete information on diabetes-specific variables and represented the sample for this study. DRCI weights based on the magnitude of one year health care resource use and socio-demographic characteristics, ranged from -471.5 to 3081.2 for total health care costs, from -304.3 to 1582.1 for outpatient costs, and -0.19 to 0.93 for risk of hospitalization. The DRCI models predicted 7% and 9% of the variance in total and ambulatory costs, respectively. CONCLUSIONS: This study suggests an association between clinical measures of diabetes severity and health care resource and costs. Future studies are needed to validate this index in other settings. We determined rates of gastrointestinal (GI) complications among patients receiving nonsteroidal antiinflammatory drugs (NSAIDS), according to risk of GI events and adherence to Veterans Affairs (VA) NSAID prescribing guidelines; and calculated the associated costs of hospitalizations from GI events by risk and adherence to guidelines. METHODS: In November 2001, we identified 7625 patients treated with NSAIDS in the New Mexico VA Health Care System. Using VA prescribing guidelines we assessed each patient's risk for GI events (low, moderate, high) and whether their treatment adhered to VA prescribing guidelines. We then reviewed patient records for GI hospitalizations and diagnoses within the following 2 years. Our data included demographic information, hospitalizations, prescription medications, and diagnoses. Costs were based upon 2002 Medicare reimbursement values. We compared outcomes and costs by risk level and adherence to guidelines, using chi square analyses for categorical data and t-tests for costs. RESULTS: Patients at moderate and high risk (n = 2288) had more (p < 0.001) GI hospitalizations (1.86%), compared to patients at low risk (n = 5337, 0.83%) with an odds ratio of 2.24, 95% confidence interval 1.47-3.41. Adherence to guidelines was not associated with fewer hospitalizations (odds ratio 1.41, confidence interval 0.67-2.96). Among patients at moderate-risk who were hospitalized, non-adherence to criteria (n = 26) was associated with higher (p = 0.027) mean costs ($5709 ± 2991) compared to those adherent to criteria (n = 9, $4037 ± 1248). Additional hospitalization costs due to nonadherence totaled $112,099. CONCLUSION: The VA guidelines used to assess risk of GI complications from NSAIDS was related to rates of GI hospitalizations over a 2-year followup period. Rates of hospitalizations were not affected by adherence to guidelines. However, mean hospitalization costs were significantly lower among patients at moderate risk who were prescribed according to guidelines. Limitations are that the study is observational and that costs are limited to GI hospitalizations.
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PGI2 A SYSTEMATIC REVIEW OF THE EFFECTIVENESS OF TOTAL AND PARTIAL LAPAROSCOPIC FUNDOPLICATION FOR THE TREATMENT OF GORD
Boler A 1 , Howard P 2 1 Heron Evidence Development, Letchworth, Hertfordshire, United Kingdom; 2 Heron Evidence Development, Letchworth, Herts, United Kingdom With a prevalence in Western countries of around 15%, GORD is associated with considerable long-term morbidity and treatment costs. Since the introduction of laparoscopic surgery in the 1990s fundoplication has becomes a viable alternative to longterm drug therapy in difficult to treat patients. Partial fundopli-
